RXI 109

Drug Profile

RXI 109

Alternative Names: RXI-109

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RXi Pharmaceuticals
  • Class Antifibrotics; Eye disorder therapies; Oligonucleotides; Skin disorder therapies; Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Keloids; Scars
  • Phase I/II Retinal disorders

Most Recent Events

  • 03 Aug 2018 Efficacy and adverse events data from a phase I/II trial in neovascular age-related macular degeneration (NVAMD), and accompanying subretinal fibrosis released by RXi Pharmaceuticals
  • 02 Aug 2018 RXi Pharmaceuticals has patent protection for sd-rxRNA platform in European Union and Japan
  • 18 Dec 2017 Efficacy and adverse events data from a phase IIa RXI-109-1402 trial in Scars released by RXi Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top